Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high response rates to the standard front-line treatment for advanced disease with cytoreductive surgical debulking, followed by platinum/taxane-based chemotherapy, most patients eventually relapse developing drug-resistant disease. Owing to the molecular heterogeneity, genetic instability and mutagenicity of OC, increases in survival might be achieved by translating recent insights at the morpho-molecular levels to individual therapeutic strategies. Several emerging treatments have been shown to be active in platinum-sensitive (PS) recurrent OC (ROC), but an optimal strategy still has not been established. Based on the recent results, it is likely that the introduction of novel non-platinum based chemotherapies and molecular targeted therapies will have a major impact on the management of ROC. Some current strategies are focused on the extension of platinum-free interval (PFI) in patients with PS, particularly in those with partially PS disease. Apparently, the PFI extension by an effective non-platinum intervention, such as trabectedin plus pegylated liposomal doxorubicin (PLD), may reduce cumulative platinum-induced toxicities leading to longer survival after the reintroduction of subsequent platinum. The introduction of novel therapies, such as the antiangiogenic monoclonal antibody bevacizumab, opens a new field of targeted therapies in this indication. In this review, we aim to outline the therapeutic potential of new emerging approaches, particularly the role of non-platinum therapy with trabectedin in combination with PLD in patients with PS ROC. © 2013 The Authors.
Poveda, A., Ray-Coquard, I., Romero, I., Lopez-Guerrero, J., & Colombo, N. (2014). Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin. CANCER TREATMENT REVIEWS, 40(3), 366-375 [10.1016/j.ctrv.2013.08.001].
|Citazione:||Poveda, A., Ray-Coquard, I., Romero, I., Lopez-Guerrero, J., & Colombo, N. (2014). Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin. CANCER TREATMENT REVIEWS, 40(3), 366-375 [10.1016/j.ctrv.2013.08.001].|
|Tipo:||Recensione in rivista|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||Si|
|Titolo:||Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin|
|Autori:||Poveda, A; Ray-Coquard, I; Romero, I; Lopez-Guerrero, J; Colombo, N|
COLOMBO, NICOLETTA (Ultimo)
|Data di pubblicazione:||2014|
|Rivista:||CANCER TREATMENT REVIEWS|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.ctrv.2013.08.001|
|Appare nelle tipologie:||01 - Articolo su rivista|